Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Porwit

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Cancers|July 13, 2024
Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of PatientsLavanya Lokhande, Daniel Nilsson, Joana de Matos Rodrigues, et al.
Leukemia & Lymphoma|October 11, 2012
Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signaturesTherese Högfeldt, Abeer A Bahnassy, Anna Kwiecinska, et al.
Leukemia & Lymphoma|September 20, 2012
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignanciesAmir Hossein Daneshmanesh, Anna Porwit, Mohammad Hojjat-Farsangi, et al.
Leukemia & Lymphoma|July 12, 2013
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areasTherese Högfeldt, Per Johnsson, Dan Grandér, et al.
European Journal of Haematology|November 10, 2009
Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006Ingrid Thörn, Erik Forestier, Britt Thuresson, et al.
Haematologica|May 4, 2006
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromesPer Anders Broliden, Inger-Marie Dahl, Robert Hast, et al.
Leukemia Research|July 22, 2008
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemiaGudmar Lönnerholm, Ingrid Thörn, Christer Sundström, et al.
International Journal of Cancer|February 14, 2008
Hepatitis C infection and risk of malignant lymphomaClaudia Schöllkopf, Karin Ekström Smedby, Henrik Hjalgrim, et al.
Blood Advances|June 30, 2023
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphomaAnna Nikkarinen, Lavanya Lokhande, Rose-Marie Amini, et al.
International Journal of Cancer|August 16, 2008
Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphomaFrida Schain, Ylva Tryselius, Jan Sjöberg, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Cancers|July 13, 2024
Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of PatientsLavanya Lokhande, Daniel Nilsson, Joana de Matos Rodrigues, et al.
Leukemia & Lymphoma|October 11, 2012
Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signaturesTherese Högfeldt, Abeer A Bahnassy, Anna Kwiecinska, et al.
Leukemia & Lymphoma|September 20, 2012
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignanciesAmir Hossein Daneshmanesh, Anna Porwit, Mohammad Hojjat-Farsangi, et al.
Leukemia & Lymphoma|July 12, 2013
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areasTherese Högfeldt, Per Johnsson, Dan Grandér, et al.
European Journal of Haematology|November 10, 2009
Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006Ingrid Thörn, Erik Forestier, Britt Thuresson, et al.
Haematologica|May 4, 2006
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromesPer Anders Broliden, Inger-Marie Dahl, Robert Hast, et al.
Leukemia Research|July 22, 2008
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemiaGudmar Lönnerholm, Ingrid Thörn, Christer Sundström, et al.
International Journal of Cancer|February 14, 2008
Hepatitis C infection and risk of malignant lymphomaClaudia Schöllkopf, Karin Ekström Smedby, Henrik Hjalgrim, et al.
Blood Advances|June 30, 2023
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphomaAnna Nikkarinen, Lavanya Lokhande, Rose-Marie Amini, et al.
International Journal of Cancer|August 16, 2008
Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphomaFrida Schain, Ylva Tryselius, Jan Sjöberg, et al.
Pageof 12